MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
18.98
-0.19 (-0.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous close19.17
Open19.25
Bid19.02 x 800
Ask19.10 x 4000
Day's range18.92 - 19.48
52-week range18.92 - 42.50
Volume5,052,496
Avg. volume7,362,411
Market cap9.783B
Beta (3Y monthly)1.59
PE ratio (TTM)41.26
EPS (TTM)0.46
Earnings date6 Aug 2019 - 12 Aug 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend date2007-06-27
1y target est31.56
  • Amgen (AMGN) Offers to Acquire Drug Discovery Platform
    Zacks3 days ago

    Amgen (AMGN) Offers to Acquire Drug Discovery Platform

    Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.

  • Here are the most and least volatile stocks since Trump ramped up trade conflict
    MarketWatch11 days ago

    Here are the most and least volatile stocks since Trump ramped up trade conflict

    DEEP DIVE A return to stock-market volatility no doubt has many investors worried. We have seen that over long periods, low-volatility index funds have performed better than their full-index benchmarks.

  • MarketWatch11 days ago

    Mylan's stock falls toward 7 1/2-year low; credit rating now in danger of downgrade to 'junk' at Fitch

    Shares of Mylan N.V. sank 2.7% in morning trade toward a 7 1/2-year low, after Fitch Ratings revised its outlook on the generic drug maker's credit rating to negative from stable, putting the rating in danger of a downgrade to "junk" status. Mylan's long-term issuer default rating at Fitch is BBB-, the lowest investment-grade rating. Fitch said the revised outlook reflects its expectation that gross leverage may remain elevated over the near term because of slower-than-expected revenue growth, cash generation and debt reduction. Fitch's rating and outlook is similar to S&P Global Ratings' BBB- rating with a negative outlook, while Moody's Investors Service has a Baa3 rating--one notch above "junk"--with a stable outlook. Generic drug maker stocks have been under pressure in recent weeks, and took another header on Monday after more than 40 state attorneys general filed suit against 20 makers of generic medications, alleging a conspiracy to artificially inflate prices and reduce competition. Shares of fellow generic drug maker Teva Pharmaceutical Industries Ltd. slid 6.1% in morning trade to a 1 1/2-year low. Year to date, Mylan's stock has tumbled 27.6% and Teva shares have plunged 26.2%, while the SPDR Health Care Select Sector ETF has gained 1.3% and the S&P 500 has tacked on 13.3%.

  • The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
    Zacks11 days ago

    The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

    The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

  • AbbVie Settles Humira Litigation With Boehringer Ingelheim
    Zacks11 days ago

    AbbVie Settles Humira Litigation With Boehringer Ingelheim

    AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.

  • Here's Why Generic-Drug Manufacturers Were Down Monday
    Motley Fool12 days ago

    Here's Why Generic-Drug Manufacturers Were Down Monday

    Forty-four states have brought a lawsuit against the industry.

  • Generic Drugmakers Face Antitrust Suit Alleging Price Fixing
    Zacks12 days ago

    Generic Drugmakers Face Antitrust Suit Alleging Price Fixing

    Shares of generic drugmakers decline on allegations of price fixing by 44 states.

  • Mylan Reiterates 2019 Revenue Guidance for These Segments
    Market Realist12 days ago

    Mylan Reiterates 2019 Revenue Guidance for These Segments

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidance for Europe and Rest of World In the first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance in the mid-single

  • Barrons.com13 days ago

    The Dow Plunges 617 Points Because China Is Hitting Back With Retaliatory Tariffs

    News of China’s retaliatory tariffs sent shares tumbling. The Dow Jones Industrial Average lost 2.38% to close at 25,324.99. The S&P 500 has dropped 2.41% to finish at 2811.87, and the Nasdaq Composite dropped 3.41% to close at 7647.02.

  • Barrons.com13 days ago

    2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan

    Health-care stocks and drugmakers have suffered from pre-election worries, but JPMorgan says there are still some worth buying.

  • Mylan Reiterated 2019 Revenue Growth Guidance for North America
    Market Realist13 days ago

    Mylan Reiterated 2019 Revenue Growth Guidance for North America

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)North America revenue growth trendsDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance of high-single-digits for its

  • A Look at Mylan’s Expense Guidance in Fiscal 2019
    Market Realist13 days ago

    A Look at Mylan’s Expense Guidance in Fiscal 2019

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Expense guidanceIn the first-quarter earnings conference call, Mylan (MYL) reaffirmed its guidance for fiscal 2019 SG&A (selling, general, and administrative) expenses to

  • What to Expect from Mylan’s Gross Margin and EBITDA
    Market Realist13 days ago

    What to Expect from Mylan’s Gross Margin and EBITDA

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Gross margin guidanceAt the Raymond James 40th Annual Institutional Investors Conference, Mylan (MYL) guided for an adjusted gross margin of 53.0% to 54.0% for fiscal 2019, a

  • ‘This will likely end badly’: Analysts react to Mylan’s revenue miss and earnings call
    MarketWatch15 days ago

    ‘This will likely end badly’: Analysts react to Mylan’s revenue miss and earnings call

    Shares of Mylan N.V. plunged 21% on Tuesday, as the stock headed toward its steepest one-day decline in 19 years.

  • Mylan Reiterated Fiscal 2019 Adjusted EPS Guidance
    Market Realist16 days ago

    Mylan Reiterated Fiscal 2019 Adjusted EPS Guidance

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Adjusted EPS guidanceDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed fiscal 2019 adjusted EPS guidance of $3.80 to $4.80, which would be a decline of

  • Mylan Reiterated Fiscal 2019 Revenue Guidance
    Market Realist16 days ago

    Mylan Reiterated Fiscal 2019 Revenue Guidance

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidanceIn the first-quarter earnings conference call, Mylan (MYL) reaffirmed its fiscal 2019 revenue guidance of $11.5 billion to $12.5 billion. The company expects to

  • What Are Analysts Recommending for Mylan after Q1 Results?
    Market Realist16 days ago

    What Are Analysts Recommending for Mylan after Q1 Results?

    Is Mylan an Attractive Pick after Q1 Results?Stock price movementsOn May 7, Mylan (MYL) reported first-quarter results. The company reported revenues of $2.50 billion, a YoY decline of 7% or around $200 million short of the consensus estimate.

  • Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates
    Zacks18 days ago

    Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates

    Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.

  • Company News For May 8, 2019
    Zacks18 days ago

    Company News For May 8, 2019

    Companies In The News Are: MYL,AIG,ARMK,ATKR

  • Barrons.com19 days ago

    The Dow Slumped 473 Points Because No One Wins a Trade War

    Market weakness could help bring both sides back together, but if tensions corporate confidence and capital spending could take a hit.

  • Associated Press19 days ago

    AIG and SolarEdge rise while Mylan and Phibro fall

    Stocks that moved substantially or traded heavily on Tuesday: American International Group Inc., up $3.19 to $50.30 The insurer reported solid underwriting gains in the first quarter and profit beat Wall ...

  • Mylan Suffers Biggest Drop in Almost Two Decades Amid Drug Pain
    Bloomberg19 days ago

    Mylan Suffers Biggest Drop in Almost Two Decades Amid Drug Pain

    Mylan, one of the world’s biggest makers of generic drugs, has faced manufacturing problems, competition and declining prices that have created “unprecedented volatility,” Chief Executive Officer Heather Bresch said on a call with investors after reporting first-quarter results. “There is a tremendous amount of work being done” by the strategic committee, which will provide an update in the “near term,” Bresch said on a conference call after the company reported first-quarter earnings. Investors, however, were in no mood to wait, and Mylan shares fell 24 percent to $21.53.

  • Mylan N.V. (MYL) Q1 2019 Earnings Call Transcript
    Motley Fool19 days ago

    Mylan N.V. (MYL) Q1 2019 Earnings Call Transcript

    MYL earnings call for the period ending March 31, 2019.

  • Epipen Parent's Faceplant Is a Cautionary Tale for Botox Maker
    Bloomberg19 days ago

    Epipen Parent's Faceplant Is a Cautionary Tale for Botox Maker

    Mylan’s sales missed Wall Street targets and the company offered no update on a strategic review that’s been in progress since August. Allergan’s quarter was saved by its blockbuster Botox, which helped the company raise its full-year guidance. While both companies disappointed shareholders, it wouldn’t fair to put Allergan in the same basket as Mylan; it isn’t in quite the same dire straits.

  • Mylan's Struggles Continue in the First Quarter
    Motley Fool19 days ago

    Mylan's Struggles Continue in the First Quarter

    The drugmaker's challenges in the U.S. generics market and problems at a manufacturing facility weighed on its first-quarter revenue and earnings.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes